Stock Research: Mayne Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Mayne Pharma

ASX:MYX AU000000MYX0
12
  • Value
    37
  • Growth
    50
  • Safety
    Safety
    42
  • Combined
    31
  • Sentiment
    25
  • 360° View
    360° View
    12
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Mayne Pharma Group Limited is a specialty pharmaceutical company. It operates in Women’s Health, Dermatology, and International segments and distributes products like NEXTSTELLIS and ANNOVERA. The company operates in the United States and Australia. In the last fiscal year, the company had a market cap of $267 million, profits of $151 million, and revenue of $264 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 12 (better than 12% compared with alternatives), overall professional sentiment and financial characteristics for the stock Mayne Pharma are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Mayne Pharma. The consolidated Growth Rank has a good rank of 50, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 50% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 42 means that the share price of Mayne Pharma is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 58% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 37, which means that the company has a riskier financing structure than 63% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 25, indicating professional investors are more pessimistic about the stock than for 75% of alternative investment opportunities. ...read more

more
Index
ASX 300
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
42 40 54 89
Growth
50 84 75 49
Safety
Safety
37 33 53 24
Sentiment
25 40 86 20
360° View
360° View
12 47 92 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
32 60 22 57
Opinions Change
50 50 100 50
Pro Holdings
n/a 1 78 24
Market Pulse
64 69 70 25
Sentiment
25 40 86 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
42 40 54 89
Growth
50 84 75 49
Safety Safety
37 33 53 24
Combined
31 55 71 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
86 86 86 24
Price vs. Earnings (P/E)
80 82 87 93
Price vs. Book (P/B)
79 59 75 95
Dividend Yield
1 1 1 100
Value
42 40 54 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
37 71 80 93
Profit Growth
30 72 4 1
Capital Growth
40 56 50 71
Stock Returns
94 70 99 31
Growth
50 84 75 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
67 59 65 22
Refinancing
54 58 83 77
Liquidity
4 4 8 8
Safety Safety
37 33 53 24

Similar Stocks

Discover high‑ranked alternatives to Mayne Pharma and broaden your portfolio horizons.

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Shionogi

TSE:4507
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Towa Pharmaceutical

TSE:4553
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.